Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation
Top Cited Papers
- 11 July 2008
- journal article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 21 (4), 492-493
- https://doi.org/10.1111/j.1755-148x.2008.00475.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Factors Affecting Survival in Patients with Anal MelanomaThe American Surgeon, 2006
- Somatic Activation of KIT in Distinct Subtypes of MelanomaJournal of Clinical Oncology, 2006
- Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaCancer, 2006
- An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patientsMelanoma Research, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Lack of clinical efficacy of imatinib in metastatic melanomaBritish Journal of Cancer, 2005
- Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM)Journal of Clinical Oncology, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003